Since the comprehensive recommendations for the management of acute promyelocytic
leukemia (APL) reported in 2009, several studies have provided important insights …

Sentrin/small ubiquitin-like modifier (SUMO) is protein modification pathway that regulates
multiple biological processes, including cell division, DNA replication/repair, signal …

TP53 is the most frequently mutated gene in cancer, yet these mutations remain
therapeutically non-actionable. Major challenges in drugging p53 mutations include …

The immune system deploys a multitude of innate and adaptive mechanisms not only to
ward off pathogens but also to prevent malignant transformation (“immune surveillance”) …

The field of Traditional Chinese Medicine (TCM) represents a vast and largely untapped
resource for modern medicine. Exemplified by the success of the antimalarial artemisinin …

Reactive oxygen species (ROS) are constantly generated and eliminated in the biological
system, and play important roles in a variety of normal biochemical functions and abnormal …

Trivalent arsenic (AsIII) is an effective agent for treating patients with acute promyelocytic
leukaemia, but its ionic nature leads to several major limitations like low effective …

Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia.
Morphologically, it is identified as the M3 subtype of acute myeloid leukemia by the French …

A wide array of chronic inflammatory conditions predispose susceptible cells to neoplastic
transformation. In general, the longer the inflammation persists, the higher the risk of cancer …

Recent clinical trials have demonstrated that the immense majority of acute promyelocytic
leukemia (APL) patients can be definitively cured by the combination of two targeted …